Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 9/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 9/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27031187 | 0.89 | ACHE (0.34) | DDB1CRBNBCHEACHE | |
| SCHEMBL27031107 | 0.88 | DDB1 (0.41) | DDB1CRBNGPR119 | |
| SCHEMBL29930514 | 0.88 | DDB1 (0.41) | DDB1CRBNGPR119 | |
| SCHEMBL29930874 | 0.87 | DDB1 (0.40) | DDB1CRBNGPR119USP30 | |
| SCHEMBL27031146 | 0.87 | DDB1 (0.40) | DDB1CRBNGPR119USP30 | |
| SCHEMBL29930608 | 0.86 | CHRM2 (0.34) | DDB1CRBNGPR119BCHEACHE | |
| SCHEMBL27031088 | 0.86 | DDB1 (0.38) | DDB1CRBNGPR119USP30 | |
| SCHEMBL29930847 | 0.86 | DDB1 (0.38) | DDB1CRBNGPR119USP30 | |
| SCHEMBL29930726 | 0.85 | DDB1 (0.39) | DDB1CRBNGPR119 | |
| SCHEMBL27031216 | 0.85 | DDB1 (0.39) | DDB1CRBNGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276964-A1 | Benzisoxazole Derivatives and Uses thereof | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-09-04 | — | — | US | disclosed |
| EP-4308559-A1 | BENZISOXAZOLE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022195355-A1 | BENZISOXAZOLE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276964-A1 | Benzisoxazole Derivatives and Uses thereof | HBZ, ZFX, WIZ | DDB1 1526/4885CRBN 820/4885GPR119 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.